| scholarly article | Q13442814 |
| P50 | author | Michael P. Busch | Q6833284 |
| P2093 | author name string | Claire Cameron | |
| Brian Custer | |||
| Steven Kleinman | |||
| Dana Devine | |||
| Louis Katz | |||
| Jutta Preiksaitis | |||
| Ken Murphy | |||
| Boris Kralj | |||
| Ian Matheson | |||
| P2860 | cites work | Blood screening for influenza | Q33883993 |
| Clinical characteristics and functional outcomes of West Nile Fever | Q34346420 | ||
| Prognosis after West Nile virus infection | Q40411672 | ||
| Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. | Q44140323 | ||
| P433 | issue | 12 | |
| P921 | main subject | emerging pathogen | Q108429945 |
| P304 | page(s) | 2592-2606 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Transfusion | Q15758500 |
| P1476 | title | Modeling the risk of an emerging pathogen entering the Canadian blood supply | |
| P478 | volume | 50 |
| Q38052141 | A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States |
| Q58701334 | Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system |
| Q40318288 | Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. |
| Q46212766 | Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation |
| Q48236668 | Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada |
| Q87645999 | Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States |
| Q36817997 | Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century |
| Q40220382 | Estimating the transfusion transmission risk of Q fever |
| Q50465183 | Getting to know the unknown. |
| Q42288202 | Modeling the transmission risk of emerging infectious diseases through blood transfusion |
| Q47114206 | Pathogen Inactivation of Cellular Blood Products-An Additional Safety Layer in Transfusion Medicine |
| Q47573759 | Pathogen reduction treatment alters the immunomodulatory capacity of buffy coat-derived platelet concentrates |
| Q47577493 | Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling |
| Q50217763 | Quantitative analysis of plasma proteins in whole blood-derived fresh frozen plasma prepared with three pathogen reduction technologies |
| Q39642986 | Risk of transfusion-transmitted chikungunya infection and efficacy of blood safety implementation measures: experience from the 2009 epidemic in Songkhla Province, Thailand |
| Q40611312 | Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation |
| Q38109665 | Update on the use of pathogen-reduced human plasma and platelet concentrates |
| Q90743513 | [Emerging infectious diseases in the context of blood safety] |
Search more.